Liver fibrosis breakthrough with Optimer® p... | 30-Jun-2025 | 07:00 | RNS |
Agreement with global life sciences leader | 25-Jun-2025 | 07:00 | RNS |
Unilever second Optimer development programme | 30-May-2025 | 07:00 | RNS |
Aptamer Announces New Data at ASGCT | 15-May-2025 | 07:01 | RNS |
Optimer licensing agreements and repeat contracts | 15-May-2025 | 07:00 | RNS |
Alzheimer’s test advanced and royalty agre... | 06-May-2025 | 07:00 | RNS |
Licensing agreed for Optimer as vaccine adjuvant | 30-Apr-2025 | 07:00 | RNS |
Interim Results | 11-Mar-2025 | 07:00 | RNS |
TR-1: Standard form notification of major holdings | 27-Feb-2025 | 12:50 | RNS |
Block Listing Interim Review | 25-Feb-2025 | 07:01 | RNS |
Notice of Results and Investor Presentation | 25-Feb-2025 | 07:00 | RNS |
Issue of Equity in lieu of Director fees | 28-Jan-2025 | 14:56 | RNS |
Half Year Trading Update | 28-Jan-2025 | 07:00 | RNS |
Notification of dealings by a director/PDMR | 13-Jan-2025 | 11:40 | RNS |
Holding(s) in Company | 30-Dec-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 0.38p |
Change Today | 0.015p |
% Change | 4.11 % |
52 Week High | 0.70 |
52 Week Low | 0.21 |
Volume | 8,629,025 |
Shares Issued | 1,991.34m |
Market Cap | £7.57m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:26 | 129,698 @ 0.39p |
15:00 | 500,000 @ 0.40p |
13:48 | 27,556 @ 0.38p |
13:17 | 50,237 @ 0.40p |
13:02 | 753,768 @ 0.40p |
CEO | Arron Tolley |
CFO | Andrew Rapson |
You are here: research